Literature DB >> 9489984

Myosin light chain I grade: a simple marker for the severity and prognosis of patients with acute myocardial infarction.

T Yamada1, A Matsumori, S Tamaki, S Sasayama.   

Abstract

To establish serum myosin light chain I (MLCI) as a severity and prognostic marker for patients with acute myocardial infarction (AMI), we measured the serum levels of MLCI in 71 patients with first AMI daily for 1 week after the onset and classified them into four groups by the peak LCI: group 1, > or =2.5 ng/ml but <10 ng/ml; group 2, > or =10 ng/ml but <25 ng/ml; group 3, > or =25 ng/ml but <50 ng/ml; and group 4, > or =50 ng/ml (MLCI grade). The patients in group 1 were likely to show non-Q-wave infarction. The patients in groups 1 and 2 were likely to show redistribution on exercise thallium-201 scintigraphy, suggesting frequent residual ischemia in these groups. The patients in group 4 were likely to show higher Forrester's subset and lower cardiac index at admission and lower left ventricular ejection fraction at discharge. Recurrent angina was equally found in all groups. Severe complications or death were found in patients in groups 3 and 4. Thus the MLCI grade can be used as a simple marker for evaluating the severity of patients with AMI.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9489984     DOI: 10.1016/s0002-8703(98)70101-2

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  5 in total

1.  The relative utility of cardiac troponin I, creatine kinase-MBmass, and myosin light chain-1 in the long-term risk stratification of patients with chest pain.

Authors:  Graham S Hillis; Pamela Taggart; Delana Wardlaw; Lorraine Hillis; Ning Zhao; William C Dalsey; Antoinette Mangione
Journal:  Clin Cardiol       Date:  2003-03       Impact factor: 2.882

2.  Cardiac Myosin Promotes Thrombin Generation and Coagulation In Vitro and In Vivo.

Authors:  Jevgenia Zilberman-Rudenko; Hiroshi Deguchi; Meenal Shukla; Yoshimasa Oyama; Jennifer N Orje; Zihan Guo; Tine Wyseure; Laurent O Mosnier; Owen J T McCarty; Zaverio M Ruggeri; Tobias Eckle; John H Griffin
Journal:  Arterioscler Thromb Vasc Biol       Date:  2020-02-27       Impact factor: 8.311

3.  Combined subthreshold dose inhibition of myosin light chain phosphorylation and MMP-2 activity provides cardioprotection from ischaemic/reperfusion injury in isolated rat heart.

Authors:  Virgilio J J Cadete; Jolanta Sawicka; Lane K Bekar; Grzegorz Sawicki
Journal:  Br J Pharmacol       Date:  2013-09       Impact factor: 8.739

4.  Utility of cardiac troponin I, creatine kinase-MB(mass), myosin light chain 1, and myoglobin in the early in-hospital triage of "high risk" patients with chest pain.

Authors:  G S Hillis; N Zhao; P Taggart; W C Dalsey; A Mangione
Journal:  Heart       Date:  1999-11       Impact factor: 5.994

Review 5.  Acute actions and novel targets of matrix metalloproteinases in the heart and vasculature.

Authors:  A K Chow; J Cena; R Schulz
Journal:  Br J Pharmacol       Date:  2007-06-25       Impact factor: 8.739

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.